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Title:  
Unlicensed medicines use: A UK guideline analysis using AGREE II 
 
Introduction 
 
An unlicensed medicine (ULM) is a medicinal product which has not been approved by a relevant 
regulatory body such as the Medicines and Healthcare Products Regulatory Agency (MHRA) in the 
UK. The term ‘unlicensed medicine’ incorporates a number of different categories of product which 
within the UK includes medicines manufactured in an MHRA licensed facility, medicines 
manufactured on a pharmacy premises under the supervision of  a pharmacist and medicines 
imported from abroad without adoption of their native medicinal license by the MHRA. Within each of 
these categories, there is a varying range of safety and quality checks which are made prior to supply 
of the product. As with other medicines regulators, the legislation within the UK allows the use of 
unlicensed medicines for circumstances when existing licensed products are unavailable, unsuitable, 
or are no longer able to meet the clinical needs of the patient. However, as there is no pharmaceutical 
license holder for an unlicensed medicine, the legal liability for their use rests between the prescriber 
and the dispensing pharmacist. Whilst some manufacturers will take some responsibility for the 
quality of the product, any adverse reactions relating to the medicine would be accountable to the 
prescriber who initiated the medicine and the pharmacist who dispensed it.  
 
In the UK, an industry has been created around the manufacture of unlicensed medicines[1] and there 
is also widespread manufacture within the National Health Service (NHS) in hospital manufacturing 
laboratories[2]. Prescribing data from primary care within the NHS reveals that their use is widespread 
and that unlicensed products cause a significant financial burden on the health system[3]. In the 12 
month period to September 2016 there was over £75m spent on unlicensed medicines dispensed in 
community pharmacies in England [4].  
 
There is limited detailed guidance for the prescribing and dispensing of ULMs. Overarching principles 
have been set out by the MHRA [5], however the main recommendation is that a licensed medicinal 
product should be used in preference to an unlicensed medicine. Use of an ULM from any category of 
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source will have its own considerations depending on individual patient need and the extent to which 
quality and safety wish to be assured. Therefore this high level guidance does not facilitate  
prescribers and pharmacists to make informed patient-level decisions about the use of unlicensed 
medicines. All medicines regulators highlight that ULMs have not undergone the rigorous safety 
checks required to obtain approval[5–8]. 
 
Internationally, the European Medicines Agency (EMA) allows member states to use ‘unauthorized 
medicines’ in the same way as the UK. The Food and Drug Administration (FDA) in the United States 
refers to the use of unlicensed medicines as “Pharmacy Compounding” and the Therapeutic Goods 
Administration (TGA) in Australia has a defined process for their use of ‘unapproved therapeutic 
goods’. Additionally in the UK, unlicensed medicines are also referred to as “Specials”, referring to the 
manufacturing facilities that make ULMs also being known as “Specials laboratories”. For the 
purposes of this article we will use the term “unlicensed medicine” to incorporate all of these terms. 
For clarity, the terms “off-label” and “unlicensed use” describe using a licensed medicinal product for 
use outside of its approved particulars. For the purpose of this study, we focused on guidelines which 
were aimed at the use of unlicensed medicines. However many of these documents also incorporated 
information around “off-label” and “unlicensed use” of medicines, and so references to these were 
also incorporated where these were mentioned in relation to using unlicensed medicines. 
 
Aims and objectives 
The aim of the guideline analysis was to: 
x Assess the quality of guidelines developed to support use of ULMs within primary and 
secondary/ tertiary care using an appropriate validated tool 
x Conduct a thematic analysis of the content of these guidelines 
x To use these two data analysis techniques to identify areas of good agreement and areas for 
concern 
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Methods 
 
Guideline document collection 
Guidelines were sought nationally for inclusion in the analysis. This was done through email requests, 
website and database searches. Email requests for unlicensed medicines guidelines were sent out 
locally and nationally through networks including local pharmaceutical committees, medicines 
management service providers, the Association of English Chief Pharmacists Network, the 
Association of British Pharmaceutical Specials Manufacturers and the Company Chemists 
Association. Notices were also added to electronic discussion boards on the UK Clinical Pharmacy 
Association and the Royal Pharmaceutical Society networks. The request sought any existing 
documentation guiding the procurement, use, administration or dispensing of unlicensed medicines. 
NHS organisation websites including NHS Trusts, Clinical Commissioning Groups and Local 
Pharmaceutical Committee were also searched for published guidelines. Websites of health 
organisations within the North East and North Cumbria Local Clinical Research Network Area were 
also hand searched for published guidelines for inclusion. 
 
A search for guidelines from published literature was also performed between May 2015 and June 
2015, searching the full text articles using the search terms "unlicensed medicine" OR  "specials" 
AND “policy” OR “guideline” OR “framework” OR “standard operating procedure” OR “standardized 
operating procedure” OR “recommendation” in Medline, International Pharmaceutical Abstracts, ISI 
Web of Knowledge, PubMed, Embase and Google Scholar (Figure 1). 
 
Evaluation of the guidelines was carried out against inclusion and exclusion criteria (Table 1).  Where 
guidelines covered more than the use of unlicensed medicines e.g. prescribing policies, only the 
relevant sections were included in the analysis. For the purpose of this guideline analysis, we defined 
an unlicensed medicine as any medicinal product which does not possess a marketing authorisation 
from the MHRA (formerly known as a product license in the UK) and is intended for use as part of 
NHS treatment. We excluded guidelines which only dealt with off-label use of medicines. 
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Appraisal of Guidelines for Research & Evaluation Instrument II (AGREE II)  
The AGREE II tool was used to evaluate the quality of the guidelines.  AGREE II is an internationally 
recognised, validated tool [10] used to assess both the quality and rigour of practice guidance by 
generating an overall guideline score [9]. It utilises 23 pre-validated items scored between 1 (strongly 
disagree) and 7 (strongly agree), organised into 6 domains: 
o  Scope and Purpose 
o  Clarity of Presentation 
o  Rigour of Development  
o  Editorial Independence  
o  Stakeholder Involvement  
o  Applicability 
 
Each of these domains was scored for each of the unlicensed medicine guidelines included in the 
analysis. Scope and purpose is the domain which scores the extent to which the guideline is clear 
around why the ULM guideline is required and what elements of unlicensed medicines use will be 
included within it, for example prescribing, procurement, dispensing. Clarity of presentation allows 
scoring around whether it is clear what is expected from those using the guideline in terms of actions 
around ULM use. Rigour of development evaluates the use of evidence in formulating 
recommendations presented in ULM guidelines, for example clinical trials for recommending specific 
products. Editorial independence ascertains whether those who have been involved in writing the 
guideline are likely to have made decisions in an objective way and whether there may be conflicts of 
interest. This includes considerations such as whether an author stands to profit from use of a 
particular supplier or product which may be contained within the guideline. Stakeholder involvement 
ascertains if the right people have been involved in the process of developing the guideline, in the 
case of unlicensed medicines have the view of patients, doctors, dentists, nurses, pharmacists been 
included. And finally the applicability domain assesses whether the guideline authors considered how 
their recommendations can be best implemented and monitored through the provision of tools to 
facilitate guideline adoption, for example patient information leaflets, audit tools etc.  
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All 23 items were scored independently by two researchers (GD and LP). It is important to note that 
guideline ratings such as AGREE II do require a level of judgement. Both are pharmacists teaching 
within a UK university and have extensive experience in the NHS. GD has a background in primary 
care as in community pharmacy, within GP practices and at a strategic level within a commissioning 
organisation. LP has a background in secondary care pharmacy practice and is an independent 
pharmacist prescriber. Both have had extensive experience of unlicensed medicines as part of their 
practice from a range of different viewpoints. Both completed online training on the use of the AGREE 
II tool. 
 
As per guidance from AGREE, a score of 1 was used where the information required to score an item 
was absent. The scores within each of the 6 domains were then used to calculate the overall domain 
score for each document as well as providing an overall guideline score for all included 
documentation (http://www.agreetrust.org/). A score of more than 60% has previously been 
considered the threshold for what is considered good quality [11–13]. 
 
Thematic Analysis 
Thematic analysis was also conducted on the documentation, using constant comparison to compare 
between documents and emerging categories [14].  To generate initial themes GD and LP analysed 8 
of the 52 documents concomitantly to ensure codes were identified and labelled consistently..  The 
remaining guideline documents were then thematically analysed independently by both researchers 
prior to gaining consensus on the final themes.  NVivo 10, a qualitative data software package, was 
used to manage the large volume of data.  
 
Results 
 
Fifty two guideline documents were included in the analysis with the documents originating from a 
range of settings (see Table 2) and taking various formats. The origin of the guideline documents is 
anonymised due to commercial sensitivity. 
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AGREE II Scoring 
 
The AGREE II scoring results by domain and guideline setting can be found in Table 3. In five out of 
the six AGREE II quality domains, guidelines from the primary care setting had the lowest scores. 
Guidelines from professional bodies had the highest scores in five out of the six AGREE II domains. 
Guidelines from the NHS secondary and tertiary care setting generally had higher scores that those 
from the primary care setting and were close to those produced by professional bodies.  
 
The scores revealed that the 52 documents performed well in both the Scope and Purpose (70.6%) 
and the Clarity of Presentation (70.4%) domains.  The majority of the documents outlined their 
specific objectives clearly, their scope was well described and the target audience was easily 
identifiable; the presentation of information was good, with the provision of specific and unambiguous 
key recommendations.  
 
In contrast, the Rigour of Development domain (12.1%) and the Editorial Independence domain 
(2.6%) scored very poorly.   A lack of documented reference to a clear evidence base contributed to 
the poor score in Rigour of Development. Editorial Independence was unclear in most documents, 
lacking information on funding bodies or competing interests in the development group.  
 
The Stakeholder Involvement score (30%) revealed that it was not always apparent in the guidelines if 
the development group included a diverse mix of healthcare professionals.  The involvement of the 
target population (patients within the NHS) also scored poorly. There was little or no evidence of 
involvement of patients across all guidelines.  
 
The Applicability domain score was relatively low (23.9%). Whilst some documents provided advice 
and tools to aid implementation of their recommendations, many did not and the potential barriers and 
facilitators to implementation were often unacknowledged.  
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On an individual guideline level, none of the guidelines included scored above 60% across all 5 
domains. Four guidelines did score more than 60% for Stakeholder Involvement, two of these were 
from NHS Secondary and Tertiary care settings and two were published by professional bodies. None 
of the guidelines included in the analysis scored above 60% for Rigour of Development, Editorial 
Independence or Applicability.  
 
Thematic Analysis 
Thematic analysis revealed four parent themes across the documentation: accepting professional 
responsibility; the practicalities of using an ULM; risk versus benefit analysis; and controlling access 
to the use of ULMs. Within these themes several sub-themes were contained which are summarised 
in Table 4 and discussed below. 
 
Professional responsibility  
Consistent references were made to the need for awareness of the unlicensed status of the 
medicines and there were a range of definitions (Table 5) in the documentation, although there was 
consensus that an unlicensed medicine was a product without a marketing authorisation..  
 
There was a focus in the guidelines on prescribers’ responsibility to be aware that the medicine being 
initiated was unlicensed. There were also references to pharmacy staff, nurses, patients, carers and 
those commissioning NHS services to also be aware. It was sometimes highlighted that prescribers 
may be unaware of the unlicensed status of a medicine and some documents provided guidance on 
status identification. Awareness was not just linked to licensing status, but also included 
understanding the potential implications in terms of prescribing, administration, procurement and 
supply. A wide range of professional bodies and legislation highlighting the responsibilities of 
individuals and organisations was referenced. The terminology used in the documentation varied 
between responsibility, accountability and liability. 
 
Usage practicalities  
Most documentation dealt with the practicalities of using ULMs well. The chronological stages 
represented in the process of use included:  i) prescribing; ii) procurement; iii) storage; iv) dispensing 
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and v) administration. Some documents also described quarantining unlicensed medicines following 
procurement but prior to dispensing. Clinical review of the patient for the ongoing appropriateness of 
use was also a commonly occurring theme.  Many guidelines contained associated paperwork in 
relation to handling/use. This was well described and included: information about manufacturers; the 
need for documented records of discussions with patients; written request orders and capturing 
justifications for the use of the unlicensed medicine. 
 
Procurement processes were described in detail, including considerations around consistency of 
product, supplier identities and timeliness of supply. Information was available in many of the 
documents to support selection of a pharmaceutical formulation, including advice on availability of 
different formulations and the choice of formulation components used. The need for assurance of 
product quality was a strongly emerging theme, with frequent reference to the need for sourcing from 
“reputable” suppliers. However, many guidelines did not provide a list of reputable suppliers or 
discuss how to recognise manufacturers as being reputable.  This was reflected during the AGREE II 
scoring within the Applicability domain where the average score for the item “the guideline provides 
advice and/or tools on how the recommendations can be put into practice” was 3.9. 
 
Pharmacists and the wider pharmacy team were referred to in managing use. Pharmacists were 
described in the “checking” of prescriptions, both in a clinical screening process for appropriateness 
and in accuracy checking of the dispensed product.  The need for pharmacists to communicate 
effectively with prescribers and other healthcare professionals on the unlicensed status of the product 
and its appropriate use was frequently included. Pharmacists were also portrayed as sources of 
information and advice to professionals and patients. 
 
Many documents discussed the need for informed patient consent prior to using an unlicensed 
medicine and the provision of information in leaflets and/or verbal communication.  
 
The theme “continuing treatment” was mainly in relation to the transfer of prescribing from secondary 
or tertiary care to primary care. A small number of documents also referenced the need for 
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communication with the community pharmacy responsible for continuation of supply following transfer 
of care. 
 
Risk versus benefit 
All guidelines covered some element of identifying, stratifying and/or mitigating risks.  However, this 
was very variable and contributed in part to the low score of 12.1% in the domain of Rigour of 
Development.  Within this domain, the item “the health benefits, side-effects, and risks have been 
considered in formulating the recommendations” had an average score of 2.6 which supports the 
variability observed in the thematic analysis.  In establishing the benefit of using an ULM, there was 
reference made to the need for evidence to support the clinical decision making process – a small 
proportion made reference to the use of medicines information departments to aid in gathering 
evidence.  More common was the use of informal methods to measure benefit, such as whether the 
patient’s clinical condition seems to improve or whether the patient was more easily able to self-
administer the medication. This was also reflected in the AGREE II scoring within the item “the 
guideline presents monitoring and/or auditing criteria” demonstrating an average score of 1.9 from all 
documents, highlighting few formal pathways of reviewing practice and updating policy.  In a small 
number of cases there was mention that there should be a requirement to publish findings (positive 
and/or negative) to support future use of ULMs by practitioners. 
 
Attempts to place ULMs in the context of other potential treatment options were prevalent. Whilst 
there was strong agreement across the documentation that a licensed medicine should be used in 
preference to an unlicensed one, the guidelines differed in the scope of alternatives that were 
considered. A description of the alternatives that were described in the documentation can be found in 
Table 6. The preference order in which these were placed was inconsistent between guidelines. 
Another prevalent message was that in some instances an unlicensed medicine was an appropriate 
option for a patient and reassurance that their use was common. This was particularly evident in the 
paediatric setting. 
 
Risks referred to the potential side effects and product preparation.  The need to report any adverse 
drug reactions was reinforced, often with reference to the Yellow Card Scheme [15].  Additional 
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internal reporting was also required by some of guidelines, making reference to contacting pharmacy 
departments where unlicensed medicines were manufactured on-site.  Some also referred to the 
need to report product defects and medication errors. 
 
There was overall agreement across documents that an unlicensed medicine generally posed a 
greater risk to patient safety than a licensed medicine.  Some described strategies for the risk 
assessment of all unlicensed medicines in order to identify and minimise some of the associated 
risks.  There were varying levels of detail; some incorporated risk assessment documentation, others 
included strategies for mitigating the identified risks. There is a list of considerations that were 
described in the documentation as part of risk assessment for unlicensed medicines in Table 7. 
 
Controlling use  
Restricting use of ULMs was described in many cases by limiting product use to meet individual 
patient needs, for example allergies to excipients in licensed products.  
A requirement for organisational approval was evident mainly within the secondary or tertiary care 
setting prior to the use of an ULM. Some professional bodies such as the British Association of 
Dermatologists[16] have published a list of recommended ULMs and their associated uses.  
 
Prescriber constraints usually related to seniority, limiting initiation to consultant grades rather than 
junior medical staff. Some guidelines indicated restricted prescribing to secondary or tertiary care, 
identifying some ULMs as unsuitable for transferring to primary care. Many documents described 
using audits to ensure that unlicensed medicines were being used in accordance with the restrictions 
laid out within the guidelines but overall this was not detailed.  Many referred to general auditing 
against the guideline rather than specifying any particular methods, measures or outcomes to be used 
– this was also supported by the AGREE II score within the Applicability domain. 
 
Costs relating to ULMs were a common feature of the documentation. Some simply highlighted 
variability and the need for sourcing from cost-effective suppliers.  Others made specific 
recommendations stating the preferred suppliers and details of the costs. Some guidelines made 
reference to the preferred use of a product included in the Drug Tariff [17] Part VIIIB, a standardised 
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price list which has been created for the reimbursement for a select number of unlicensed medicines 
dispensed in primary care in England and Wales . A number also made reference to ensuring that a 
licensed product was used in preference to an unlicensed one even where the latter may be more 
expensive. 
 
Discussion 
The scores from the AGREE II scoring found wide variability in the quality of guidelines for unlicensed 
medicines. We have also found that there is a lack of consistency of content across UK ULM 
guidelines. Whilst there was some agreement in content across the unlicensed medicines guidelines, 
a lack of a consistent approach is a cause for concern. 
 
Inconsistency in content between guidelines may in part be due to the lack of a clear evidence base 
on which the guidelines have been developed. Lack of an evidence base for using unlicensed 
medicines was consistent throughout and is evident in the poor Rigour of Development domain score.  
This low score has also been reflected in other AGREE II analyses of guidelines where evidence is 
lacking for treatment recommendations such as  paediatric headache [18] and sedation in palliative 
care [19]. Low scores identified within this analysis for  the Rigour of Development domain echo the 
findings in dermatology guideline analysis [12]. For Editorial Independence, a lack of clarity across 
funding bodies for guideline development or competing interests in the development group has also 
been found in other guidelines analysed using the AGREE II tool [12,18].  
 
In agreement with our findings, a review of dementia guidelines found that Scope and Purpose, and 
Clarity of Presentation  were the only domains that had high quality scores [20].  Our poor score for 
Stakeholder Involvement highlighted a lack of transparency in developing, writing and updating 
guidelines. Organisations who use ‘working party’ methodology, such as the National Institute of 
Health and Clinical Excellence [11,13] and the Scottish Intercollegiate Guideline Network [11,13,20], 
generally score well in this domain. The Stakeholder Involvement domain also identified a deficit in 
patient involvement in guideline development, similar to other findings using AGREE II [11,21]. 
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This study also found variation in terminology in terms of what constitutes an “unlicensed medicine” 
which is potentially misleading for both healthcare professionals and their patients.  Lack of clarity in 
describing the roles and responsibilities of the individual members of the healthcare team also exists. 
This could make implementation of such guidelines difficult and is reflected in low scores in the 
‘Applicability’ domain Other analyses have also found a wide variability in the consideration of the use 
of guidelines in practice [11,12,18,20,21]. 
 
Risk attenuation procedures for the use of ULMs were heavily focused on pharmacy teams.  In 
contrast, prescribers are seen to be responsible for the clinical decision making, documentation of 
communication with the patient and transferring use of unlicensed medicines across care settings.  
There was no guidance in the event that the primary care prescriber did not want to take over 
prescribing responsibility.  This is a difficult area as it is especially important that prescribers in 
primary care are confident in taking on the transferred responsibility from secondary or tertiary care 
[22]. 
 
It is reassuring to see that most of the guidelines made reference to involving patients in the decision 
to use a ULM. However not all guidelines provided the tools to facilitate these conversations and  
within the paediatric setting  the general public lacked knowledge about ULM use [23]. A 
questionnaire study also found that there was little knowledge of the licensing process of medication 
[24] leaving patients poorly equipped  to facilitate informed decision making and to ensure safe and 
appropriate use of their medication.  
 
The lack of consistency around the assessment of risks and benefits is probably the greatest area of 
concern revealed in this study. If there isn’t agreement about how risk in using ULMs should be 
assessed then there is likely to be variability in the products which are ultimately chosen for 
procurement. Some tools may also be based on a larger body of intelligence gained from experience 
that may not be widely shared, so organisations without this intelligence may continue to use products 
that have been disregarded elsewhere due to safety concerns. Some organisations placed 
responsibility for the entire process on a single clinician, a strategy that potentially increases the risk 
for patients as that clinician may not have the knowledge and skills to perform a comprehensive risk 
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assessment.  Other guidelines recommended involvement of the multi-disciplinary team, and it would 
be appropriate to adopt this approach more widely. The main concerns around the associated risks 
have also been documented by Chisolm [24] who argued that safety is one of the most important 
aspects when prescribing ULMs alongside efficacy.  
 
A phenomenological review of the ULM literature [25] revealed that adverse events are unreported for 
ULMs.  This is surprising given that within the guideline analysis conducted here, recommendations 
around the reporting of adverse drug reactions are evident. On the other hand, there is  little 
information in the guidelines around ensuring that a licensed product is dispensed where the 
medication is prescribed generically, a point also  highlighted by Sutherland and Waldeck [25]. This 
may be due to this information being contained within dispensary-based standard operating 
procedures not submitted as part of the call for guidelines in this study.  
 
The General Medical Council (GMC) guideline [26] states that ULMs may be prescribed where there 
is no suitable licensed alternative that can meet the patient’s need.  However, this analysis suggests 
that there is widespread use of ULMs to meet the needs of specific patient groups and for specific 
indications. These routine uses are commonly documented in local ULM guidelines and therefore are 
potentially seen to be legitimised (see also [25]).  
 
Whilst the AGREE II tool is used to assess the quality of national guidelines such as that produced by 
NICE and the guidelines included here also incorporate local guidelines and procedures, the 
standards to which these are produced in terms of process would be expected to be the same. For 
unlicensed medicines, the absence of a robust national guideline means that local procedures are 
even more important in guiding local decision making. However, we also acknowledge that the 
resources available to develop guidelines at a local level will be significantly reduced compared to that 
available to national guidance bodies. 
 
Limitations to this study 
Our analysis has given a clearer picture of the variability in content and quality of guidelines currently 
in use for ULMs within the UK.  However, 56% of these documents came from secondary and tertiary 
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care centres compared to 21% from primary care. It is unclear if the smaller number from primary care 
is due to a lack of available guidelines or a lack of submission to the project. Although there were 
submissions to the analysis from across England the submissions may not be representative of all 
guidelines within the UK. There were also no submissions from private healthcare organisations. 
Whilst all efforts were made to identify documents for inclusion, we acknowledge that there will be 
more documentation which could have been included. However, this would be almost impossible to 
collect at this large scale and analysis of all of those guidelines would be impracticable. It should be 
noted that other studies of this type have analysed much smaller samples of guideline documentation. 
We used two reviewers for the analysis which is within recommendations for using the AGREE II tool, 
however more reviewers would increase the reliability of the scores. While we also attempted to find 
information to rate guidelines using other sources that were submitting alongside guidelines or 
websites of the organisations who published the guidelines, we did not contact authors or 
organisations directly to source additional information where this was not readily available. This could 
mean that some scores could be lower due information not being available which may be available to 
users of the guideline. 
 
Document analysis can also only provide part of the picture in relation to ULM use. Here, we have 
used guidelines to explore how organisations are recommending that ULMs are handled, and these 
may not be borne out in the actions of healthcare professionals. Further research is required to 
explore how guideline recommendations translate into clinical practice. 
 
Conclusion 
 
When producing guidelines for ULM usage, organisations should pay attention to the rigour of their 
development, stakeholder involvement and editorial independence. In addition, our thematic analysis 
also identified the need to focus on professional responsibility, the practicalities of using a ULM, 
improved risk/benefit analysis and how access to the use of ULMs is controlled. 
 
A ‘formulary’ of unlicensed medicines is a potential solution to the problem of ULM use. In turn, this 
may aid improved monitoring through existing pharmacovigilance infrastructure, a process that  could 
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also be supported with dosing information for prescribers, compilation of recommended alternatives 
and other therapeutic information such as cautions, contraindications and dose adjustments. It may 
also reduce some of the organisation-level assessments that are made within the NHS and could 
release efficiency savings which has been a focus of the Carter Review [27] .However, this approach 
may run contrary to the legislative basis on which ULMs are used, that they should only be used to 
meet the needs of an individual patient. An alternative would be a legislative approach similar to that 
in Australia whereby the use of unlicensed medicines is approved centrally either for individual 
prescribers or on a case-by-case basis [7]. 
 
There is a need for national leadership in the UK to develop a strategy in relation to the use of 
unlicensed medicines. This should include clear guidance on risk assessment and their place in the 
clinical management of patients. These decisions should take into account the views of stakeholders 
from a range of expertise as well as patients. Only then can we be confident that when an ULM is 
used, all considerations have been taken into account to ensure it is the best treatment option in the 
absence of a licensed medicine. 
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Potentially relevant 
guidelines identified 
through database 
searching 
(n = 24,025) 
Potentially relevant 
guidelines identified 
through organisation 
websites in NENC LCRN 
(n = 19) 
Potentially relevant 
guidelines identified 
through Call for 
guidelines distributed 
locally and nationally 
(n = 87) 
Titles and abstracts/ 
summaries screened 
(n = 24,131) 
Records excluded 
(n = 24.076) including 
99.95% from Google 
Scholar* 
Full text documents 
assessed for eligibility 
(n = 55) 
Full text documents 
excluded 
(n = 4) 
Full text documents 
included 
(n = 51) 
References to any 
further 
documentation 
checked for further 
eligible documents 
(n = 1) 
Full text documents 
included in the AGREE II 
and thematic analysis 
(n = 52) 
*Reasons for exclusion from 
Google Scholar results 
Did not meet inclusion 
criteria: 
x Not a guideline 
x Not related to ULM 
x Non-UK i.e. 
Australian, South 
African, USA, 
Austria, Italy, 
Turkey, Nigeria 
x Text books 
x Letters 
x Related to contrast 
media 
x Related to use of 
devices 
x Not available as 
the link provided is 
expired 
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Table 1: Inclusion and exclusion criteria for guideline inclusion 
Inclusion criteria Exclusion criteria 
Guidelines on the use of unlicensed 
medicines, including prescribing, 
procurement, dispensing or administration 
aimed for use within the UK NHS 
Guidelines primarily relating to: 
x Homeopathic medicines 
x Food or dietary supplements 
x Radiopharmacy 
x Herbal medicines 
x Off-label or unlicensed use of licensed 
medicines 
x Medical devices 
x Investigational medicinal products 
x Orphan drugs 
x  
Documents identified as guidelines, policies, 
frameworks, standard operating procedures 
or providing recommendations to inform use 
(as described above) of ULMs 
x Educational materials 
x Stand-alone patient information 
leaflets 
x Formularies 
x Newsletters 
x Generalised guidance documents for 
prescribing or those relating to specific 
medicines or therapeutic areas 
x Research studies on unlicensed 
medicines use 
x  
Any setting in which unlicensed medicines 
are used  x Manufacturing guidelines 
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Table 2: Setting in which guidelines are intended for use 
Guideline setting N % 
NHS secondary and tertiary care trusts 29 56 
Professional bodies and regulators 12 23 
Primary Care  11 21 
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Table 3: Average scores (%) across the AGREE II domains and guideline  setting 
 AGREE II Domains 
Setting 
Scope 
and 
Purpose 
(%) 
Clarity of 
Presentation 
(%) 
Rigor of 
Development 
(%) 
Editorial 
Independence 
(%) 
Stakeholder 
Involvement 
(%) 
Applicability 
(%) 
Primary 
Care 
 
57.9 
 
69.4 7.1 1 20.2 17.8 
NHS 
Secondary 
and Tertiary 
Care 
73.3 69.3 12.6 1 31.5 27.3 
Professional 
Bodies 74.6 72.2 15.4 7 35.2 21.4 
Overall 
Domain 
Score 
70.6 70.4 12.1 2.6 30 23.9 
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Table 4: Themes from thematic analysis of guidelines content 
Parent theme Sub-themes 
Professional responsibility  x Understanding the definitions around 
unlicensed medicines 
x Usage awareness of patients and 
professionals 
x Individual and organisational 
responsibilities 
x References to the guidance and 
legislation  
Usage practicalities  x Selecting the pharmaceutical formulation 
x Role of the pharmacist and the wider 
pharmacy team in use management  
x Patient involvement 
x Stages of use 
x Continuing treatment  
Risk versus benefit x Evidence to support use  
x Place in the treatment of a patient and 
potential alternatives 
x Describing and assessing risk  
x Reporting of errors and adverse effects  
Controlling use  x Costs  
x Audit of use  
x Restricting use  
x Organisational decision making  
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Table 5: Different definitions used to describe unlicensed medicines 
x Specials 
x Medicines prepared by a UK manufacturer but without a UK product 
license 
x Investigational medicinal products 
x Medicines withdrawn from the UK market 
x Medicines obtained from a manufacturer with an MHRA specials 
license 
x Off-label medicines 
x Extemporaneously prepared medicines 
x Re-packed medicines 
x Chemicals used to treat rare metabolic disorders 
x Individually prepared medicines 
x Imported medicines 
x Homeopathic medicines 
x Intermediate products 
x Reconstituted medicines 
x Temporarily authorised medicines 
x Near-label use of medicines 
x Manipulation of medicines prior to administration 
x CE marked products 
x Food supplements 
x Use of medicines at variance to their licence 
x Compounding 
x Mixing of medicines 
x Compassionate medicine use 
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Table 6: Preferred options for unlicensed medicines described in UK guidelines 
Unlicensed Batch-prepared preferred to individually prepared unlicensed medicines 
Unlicensed medicines which appear in the Drug Tariff Part VIIIB 
Acceptance of 
other licensing 
Registered medical devices 
Imported medicines which are licensed in their country of origin 
Use outside of 
license 
Manipulation of a licensed dosage form, such as crushing tablets or 
opening capsules 
Products licensed for veterinary purposes but not in humans 
No medicine Review of medicines for patients with polypharmacy to potentially 
discontinue a medicine which is no longer required, rather than continue 
a medicine which is unlicensed 
Use of self-care advice rather than prescribing an unlicensed treatment 
where there is no licensed medicine available 
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Table 7: Risk assessment considerations contained in guidelines for unlicensed 
medicines 
Area Examples/ Details 
Therapeutic considerations of the active 
pharmaceutical ingredient  
Indication, dose, side effects, interactions 
Anticipated duration of use Short term course of treatment, use to fill a 
gap in supply of a licensed medicine 
Availability of analytical information for the 
product 
Certificates of conformity, certificates of 
analysis, results of regional quality 
assurance testing, results of in-house testing 
Availability of product information List of active pharmaceutical ingredient and 
excipients along with quantities, indications, 
instructions for use 
Country of origin UK, countries with whom there is a reciprocal 
acknowledgement of quality of 
pharmaceutical manufacture 
Evidence for use Whether research evidence exists, or 
whether the suggested use is known locally 
or nationally 
Supplier Whether the supplier is also the 
manufacturer, or an intermediary, if the 
manufacturer is licensed or known to the 
organisation e.g. NHS Manufacturing units 
Information for use Whether the product is labelled in English, if 
there is a patient information leaflet available 
Route of administration Products to be used topically considered to 
be of lower risk, with parenteral products 
considered higher risk 
Standard availability Is there a standard for the manufacture of 
the product such as a Pharmacopoeia 
monograph 
Whether the product is considered a 
‘medicine’ 
Products manufactured not for medicinal 
purposes such as food supplements 
Withholding treatment impact Consideration of whether the risk of 
withholding a treatment also has associated 
risks 
 
